Sartorius AG

EANS-Voting Rights: Sartorius AG
Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution

--------------------------------------------------------------------------------
  Notification of voting rights transmitted by euro adhoc. The issuer is
  responsible for the content of this announcement.
-------------------------------------------------------------------------------- 
Announcement according to Article 21, Section 1 of the WpHG (share) 
Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. Hercules,
California, USA has informed us on March 18, 2011 of the following: 
1.	Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. has informed
us in the name and on behalf of its subsidiary Bio-Rad Holding LLC, Hercules,
California, USA, that the share of voting rights of its subsidiary on October 3,
2003 has exceeded the thresholds of 5% and 10% and on that day totaled 13.38% of
the voting rights (1,252,647 voting rights) of Sartorius AG. 
Of these voting rights 13.38% (1,252,647 voting rights) are to be attributed to
Biorad Laboratories, Inc. pursuant to s. 22 subsection 1 sentence 1 no. 1 WpHG. 
Voting rights that are to be attributed are held via the following companies
which are controlled by Bio-Rad Holding LLC and whose holding of voting rights
amount to 3% each or more in Sartorius AG:
- Bio-Rad Laboratories GmbH 
2.	Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. has informed
us in the name and on behalf of its subsidiary Bio-Rad Holding LLC that the
share of voting rights of its subsidiary on November 24, 2003 has fallen below
the thresholds of 10% and 5% and on that day totaled 0% (0 voting rights) of the
voting rights of Sartorius AG. 
Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. has informed us
in the name and on behalf of its subsidiary Bio-Rad Laboratories ApS, Kobenhavn,
Denmark, that the share of voting rights of its subsidiary on November 24, 2003
has exceeded the thresholds of 5% and 10% and on that day totaled 14.10%
(1,320,137 voting rights) of the voting rights of Sartorius AG. 
Of these voting rights 14.10% (1,320,137 voting rights) are to be attributed
pursuant to sec. 22 subsection 1 sentence 1 no. 1 WpHG. 
Voting rights that are to be attributed are held via the following companies
which are controlled by Bio-Rad Laboratories ApS and whose holdings of voting
rights amount to 3% each or more in Sartorius AG:
- Bio-Rad France Holding SAS
- Bio-Rad Laboratories GmbH 
Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. has informed us
in the name and on behalf of its subsidiary Bio-Rad France Holding SAS,
Marnes-la-Coquet, France, that the share of voting rights of its subsidiary on
November 24, 2003 has exceeded the thresholds of 5% and 10% and on that day
totaled 14.10% (1,320,137) of the voting rights of Sartorius AG. 
Of these voting rights 14.10% (1,320,137 voting rights) are to be attributed
pursuant to sec. 22 subsection 1 sentence 1 no. 1 WpHG. 
Voting rights that are to be attributed are held via the following companies
which are controlled by Bio-Rad France Holding SAS and whose holdings of voting
rights amount to 3% each or more in Sartorius AG:
- Bio-Rad Laboratories GmbH 
3.	Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. has informed
us in the name and on behalf of its subsidiary Bio-Rad Laboratories ApS that the
share of voting rights of its subsidiary on September 13, 2006 has exceeded the
threshold of 25% and on that day totaled 25.02% (2,341,479 voting rights) of the
voting rights of Sartorius AG. 
Of these voting rights 25.02% (2,341,479 voting rights) are to be attributed
pursuant to sec. 22 subsection 1 sentence 1 no. 1 WpHG. 
Voting rights that are to be attributed are held via the following companies
which are controlled by Bio-Rad Laboratories ApS and whose holdings of voting
rights amount to 3% each or more in Sartorius AG:
- Bio-Rad France Holding SAS
- Bio-Rad Laboratories GmbH 
Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. has informed us
in the name and on behalf of our subsidiary Bio-Rad France Holding SAS that the
share of voting rights of our subsidiary on September 13, 2006 has exceeded the
threshold of 25% and on that day totaled 25.02% (2,341,479 voting rights) of the
voting rights of Sartorius AG. 
Of these voting rights 25.02% (2,341,479 voting rights) are to be attributed
pursuant to sec. 22 subsection 1 sentence 1 no. 1 WpHG. 
Voting rights that are to be attributed are held via the following companies
which are controlled by Bio-Rad Fraace Holding SAS and whose holdings of voting
rights amount to 3% each or more in Sartorius AG:
- Bio-Rad Labomtories GmbH 
4.	Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. has informed
us in the name and on behalf of its subsidiary Bio-Rad Luxembourg S.à.r.l.,
Luxembourg, that the share of voting rights of its subsidiary on December 19,
2007 has exceeded the thresholds of 3%, 5%, 10%, 15%, 20% and 25% and on that
day totaled 25.19% (2,357,480 voting rights) of the voting rights of Sartorius
AG. 
Of these voting rights 25.19% 2,357,480 voting rights) are to be attributed
pursuant to sec. 22 subsection 1 sentence 1 no. 1 WpHG. 
Voting rights that are to be attributed are held via the following companies
which are controlled by Bio-Rad Luxembourg S.à.r.l. and whose holdings of voting
rights amount to 3% each or more in Sartorius AG:
- Bio-Rad Laboratories ApS
- Bio-Rad France Holding SAS
- Bio-Rad Laboratories GmbH 
5.	Pursuant to sec. 21 subsection 1 WpHG Biorad Laboratories, Inc. inform us in
the name and on behalf of its subsidiary Bio-Rad Laboratories ApS that the share
of voting rights of our subsidiary on March 17, 2008 has fallen below the
thresholds of 25%, 20%, 15%, 10%, 5% und 3 % and on that day totaled 0% (0
voting rights) of the voting rights of Sartorius AG. 
end of announcement                               euro adhoc
-------------------------------------------------------------------------------- 

Further inquiry note:

Katrin Sebastian
Stellvertret. Leiterin Konzernrechtsabteilung
Tel.: 0049 (0) 551 308 3849
E-Mail: katrin.sebastian@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Original-Content von: Sartorius AG, übermittelt durch news aktuell

Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: